ID   TRI33_HUMAN             Reviewed;        1127 AA.
AC   Q9UPN9; O95855; Q5TG72; Q5TG73; Q5TG74; Q9C017; Q9UJ79;
DT   24-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 3.
DT   10-MAY-2017, entry version 177.
DE   RecName: Full=E3 ubiquitin-protein ligase TRIM33;
DE            EC=2.3.2.27;
DE   AltName: Full=Ectodermin homolog;
DE   AltName: Full=RET-fused gene 7 protein;
DE            Short=Protein Rfg7;
DE   AltName: Full=RING-type E3 ubiquitin transferase TRIM33 {ECO:0000305};
DE   AltName: Full=Transcription intermediary factor 1-gamma;
DE            Short=TIF1-gamma;
DE   AltName: Full=Tripartite motif-containing protein 33;
GN   Name=TRIM33; Synonyms=KIAA1113, RFG7, TIF1G;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA), FUNCTION, SUBUNIT, AND
RP   VARIANT THR-840.
RX   PubMed=10022127; DOI=10.1038/sj.onc.1202655;
RA   Venturini L., You J., Stadler M., Galien R., Lallemand V.,
RA   Koken M.H.M., Mattei M.-G., Ganser A., Chambon P., Losson R.,
RA   De The H.;
RT   "TIF1gamma, a novel member of the transcriptional intermediary factor
RT   1 family.";
RL   Oncogene 18:1209-1217(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND BETA), AND VARIANT
RP   THR-840.
RX   PubMed=11331580; DOI=10.1093/emboj/20.9.2140;
RA   Reymond A., Meroni G., Fantozzi A., Merla G., Cairo S., Luzi L.,
RA   Riganelli D., Zanaria E., Messali S., Cainarca S., Guffanti A.,
RA   Minucci S., Pelicci P.G., Ballabio A.;
RT   "The tripartite motif family identifies cell compartments.";
RL   EMBO J. 20:2140-2151(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM ALPHA), AND VARIANT
RP   THR-840.
RC   TISSUE=Brain;
RX   PubMed=10470851; DOI=10.1093/dnares/6.3.197;
RA   Kikuno R., Nagase T., Ishikawa K., Hirosawa M., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIV.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 6:197-205(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 76-1127 (ISOFORMS ALPHA AND BETA),
RP   CHROMOSOMAL TRANSLOCATION WITH RET, AND VARIANT THR-840.
RC   TISSUE=Thyroid;
RX   PubMed=10439047; DOI=10.1038/sj.onc.1202824;
RA   Klugbauer S., Rabes H.M.;
RT   "The transcription coactivator HTIF1 and a related protein are fused
RT   to the RET receptor tyrosine kinase in childhood papillary thyroid
RT   carcinomas.";
RL   Oncogene 18:4388-4393(1999).
RN   [6]
RP   SUBUNIT.
RX   PubMed=12096914; DOI=10.1016/S0022-2836(02)00477-1;
RA   Peng H., Feldman I., Rauscher F.J. III;
RT   "Hetero-oligomerization among the TIF family of RBCC/TRIM domain-
RT   containing nuclear cofactors: a potential mechanism for regulating the
RT   switch between coactivation and corepression.";
RL   J. Mol. Biol. 320:629-644(2002).
RN   [7]
RP   FUNCTION AS AN E3 UBIQUITIN-PROTEIN LIGASE, UBIQUITINATION OF SMAD4,
RP   INTERACTION WITH SMAD4, MUTAGENESIS OF CYS-125 AND CYS-128, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=15820681; DOI=10.1016/j.cell.2005.01.033;
RA   Dupont S., Zacchigna L., Cordenonsi M., Soligo S., Adorno M.,
RA   Rugge M., Piccolo S.;
RT   "Germ-layer specification and control of cell growth by Ectodermin, a
RT   Smad4 ubiquitin ligase.";
RL   Cell 121:87-99(2005).
RN   [8]
RP   FUNCTION, IDENTIFICATION IN A COMPLEX WITH SMAD2 AND SMAD3,
RP   INTERACTION WITH SMAD2 AND SMAD3, AND SUBCELLULAR LOCATION.
RX   PubMed=16751102; DOI=10.1016/j.cell.2006.03.045;
RA   He W., Dorn D.C., Erdjument-Bromage H., Tempst P., Moore M.A.,
RA   Massague J.;
RT   "Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of
RT   the TGFbeta pathway.";
RL   Cell 125:929-941(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-862; THR-1102 AND
RP   SER-1105, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH SMAD2 AND SMAD4.
RX   PubMed=19135894; DOI=10.1016/j.cell.2008.10.051;
RA   Dupont S., Mamidi A., Cordenonsi M., Montagner M., Zacchigna L.,
RA   Adorno M., Martello G., Stinchfield M.J., Soligo S., Morsut L.,
RA   Inui M., Moro S., Modena N., Argenton F., Newfeld S.J., Piccolo S.;
RT   "FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling,
RT   controls Smad4 monoubiquitination.";
RL   Cell 136:123-135(2009).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-763; LYS-769 AND LYS-953,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-862; THR-1102 AND
RP   SER-1105, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-862; THR-1102 AND
RP   SER-1105, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-862; THR-1051 AND
RP   SER-1119, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-515; ARG-535; ARG-577;
RP   ARG-591; ARG-598 AND ARG-604, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [18]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-334; LYS-763; LYS-769;
RP   LYS-776; LYS-793; LYS-953; LYS-1007 AND LYS-1057, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [19]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-776 AND LYS-793, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [20]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-763; LYS-769; LYS-776;
RP   LYS-793; LYS-861; LYS-1057 AND LYS-1118, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [21]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-763; LYS-769; LYS-776;
RP   LYS-793 AND LYS-1057, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to
RT   replication stress reveals novel small ubiquitin-like modified target
RT   proteins and acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [22]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-580; SER-696; LYS-811; SER-885;
RP   MET-961 AND THR-1090.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Acts as an E3 ubiquitin-protein ligase. Promotes SMAD4
CC       ubiquitination, nuclear exclusion and degradation via the
CC       ubiquitin proteasome pathway. According to PubMed:16751102, does
CC       not promote a decrease in the level of endogenous SMAD4. May act
CC       as a transcriptional repressor. Inhibits the transcriptional
CC       response to TGF-beta/BMP signaling cascade. Plays a role in the
CC       control of cell proliferation. Its association with SMAD2 and
CC       SMAD3 stimulates erythroid differentiation of hematopoietic
CC       stem/progenitor (By similarity). Monoubiquitinates SMAD4 and acts
CC       as an inhibitor of SMAD4-dependent TGF-beta/BMP signaling cascade
CC       (Monoubiquitination of SMAD4 hampers its ability to form a stable
CC       complex with activated SMAD2/3 resulting in inhibition of TGF-
CC       beta/BMP signaling cascade). {ECO:0000250,
CC       ECO:0000269|PubMed:10022127, ECO:0000269|PubMed:15820681,
CC       ECO:0000269|PubMed:16751102, ECO:0000269|PubMed:19135894}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Homooligomer and heterooligomer with TRIM24 and TRIM28
CC       family members. Interacts with SMAD4 in unstimulated cells. Found
CC       in a complex with SMAD2 and SMAD3 upon addition of TGF-beta.
CC       Interacts with SMAD2 and SMAD3. Interacts with SMAD4 under basal
CC       and induced conditions and, upon TGF-beta signaling, with
CC       activated SMAD2. Forms a ternary complex with SMAD4 and SMAD2 upon
CC       TGF-beta signaling. {ECO:0000269|PubMed:10022127,
CC       ECO:0000269|PubMed:12096914, ECO:0000269|PubMed:15820681,
CC       ECO:0000269|PubMed:16751102, ECO:0000269|PubMed:19135894}.
CC   -!- INTERACTION:
CC       Q15796:SMAD2; NbExp=6; IntAct=EBI-2214398, EBI-1040141;
CC       Q13485:SMAD4; NbExp=6; IntAct=EBI-2214398, EBI-347263;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15820681,
CC       ECO:0000269|PubMed:16751102, ECO:0000269|PubMed:19135894}. Note=In
CC       discrete nuclear dots resembling nuclear bodies. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Alpha;
CC         IsoId=Q9UPN9-1; Sequence=Displayed;
CC       Name=Beta;
CC         IsoId=Q9UPN9-2; Sequence=VSP_005774;
CC   -!- TISSUE SPECIFICITY: Expressed in stem cells at the bottom of the
CC       crypts of the colon (at protein level). Expressed in colon
CC       adenomas and adenocarcinomas (at protein level). Expressed in
CC       brain, lung, liver, spleen, thymus, prostate, kidney, testis,
CC       heart, placenta, pancreas, small intestine, ovary, colon, skeletal
CC       muscle and hematopoietic progenitors.
CC   -!- PTM: Sumoylated with SUMO1. {ECO:0000250|UniProtKB:Q99PP7}.
CC   -!- DISEASE: Note=A chromosomal aberration involving TRIM33 is found
CC       in papillary thyroid carcinomas (PTCs). Translocation
CC       t(1;10)(p13;q11) with RET. The translocation generates the
CC       TRIM33/RET (PTC7) oncogene. {ECO:0000269|PubMed:10439047}.
CC   -!- SIMILARITY: Belongs to the TRIM/RBCC family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD17259.1; Type=Frameshift; Positions=1114; Evidence={ECO:0000305};
CC       Sequence=BAA83065.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAI13548.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=CAI21895.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF119043; AAD17259.1; ALT_FRAME; mRNA.
DR   EMBL; AF220136; AAG53509.1; -; mRNA.
DR   EMBL; AF220137; AAG53510.1; -; mRNA.
DR   EMBL; AB029036; BAA83065.1; ALT_INIT; mRNA.
DR   EMBL; AL390241; CAI13548.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL035410; CAI13548.1; JOINED; Genomic_DNA.
DR   EMBL; AL390241; CAI13550.1; -; Genomic_DNA.
DR   EMBL; AL035410; CAI13550.1; JOINED; Genomic_DNA.
DR   EMBL; AL390241; CAI13551.1; -; Genomic_DNA.
DR   EMBL; AL035410; CAI13551.1; JOINED; Genomic_DNA.
DR   EMBL; AL035410; CAI21895.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AL390241; CAI21895.1; JOINED; Genomic_DNA.
DR   EMBL; AL035410; CAI21896.1; -; Genomic_DNA.
DR   EMBL; AL390241; CAI21896.1; JOINED; Genomic_DNA.
DR   EMBL; AL035410; CAI21897.1; -; Genomic_DNA.
DR   EMBL; AL390241; CAI21897.1; JOINED; Genomic_DNA.
DR   EMBL; AJ132948; CAB55313.1; -; mRNA.
DR   CCDS; CCDS872.1; -. [Q9UPN9-1]
DR   CCDS; CCDS873.1; -. [Q9UPN9-2]
DR   RefSeq; NP_056990.3; NM_015906.3. [Q9UPN9-1]
DR   RefSeq; NP_148980.2; NM_033020.2. [Q9UPN9-2]
DR   UniGene; Hs.26837; -.
DR   PDB; 3U5M; X-ray; 3.08 A; A/B/C/D/E/F/G/H/I/J/K/L=882-1087.
DR   PDB; 3U5N; X-ray; 1.95 A; A/B=882-1087.
DR   PDB; 3U5O; X-ray; 2.70 A; A/B/C/D/E/F/G/H=882-1087.
DR   PDB; 3U5P; X-ray; 2.80 A; A/B/C/D/E/F/G/H=882-1087.
DR   PDBsum; 3U5M; -.
DR   PDBsum; 3U5N; -.
DR   PDBsum; 3U5O; -.
DR   PDBsum; 3U5P; -.
DR   ProteinModelPortal; Q9UPN9; -.
DR   SMR; Q9UPN9; -.
DR   BioGrid; 119625; 77.
DR   DIP; DIP-54262N; -.
DR   IntAct; Q9UPN9; 49.
DR   MINT; MINT-2822547; -.
DR   STRING; 9606.ENSP00000351250; -.
DR   BindingDB; Q9UPN9; -.
DR   ChEMBL; CHEMBL2176772; -.
DR   iPTMnet; Q9UPN9; -.
DR   PhosphoSitePlus; Q9UPN9; -.
DR   BioMuta; TRIM33; -.
DR   DMDM; 313104270; -.
DR   EPD; Q9UPN9; -.
DR   PaxDb; Q9UPN9; -.
DR   PeptideAtlas; Q9UPN9; -.
DR   PRIDE; Q9UPN9; -.
DR   Ensembl; ENST00000358465; ENSP00000351250; ENSG00000197323. [Q9UPN9-1]
DR   Ensembl; ENST00000369543; ENSP00000358556; ENSG00000197323. [Q9UPN9-2]
DR   GeneID; 51592; -.
DR   KEGG; hsa:51592; -.
DR   UCSC; uc001eew.3; human. [Q9UPN9-1]
DR   CTD; 51592; -.
DR   DisGeNET; 51592; -.
DR   GeneCards; TRIM33; -.
DR   H-InvDB; HIX0000910; -.
DR   HGNC; HGNC:16290; TRIM33.
DR   HPA; HPA004345; -.
DR   MalaCards; TRIM33; -.
DR   MIM; 605769; gene.
DR   neXtProt; NX_Q9UPN9; -.
DR   OpenTargets; ENSG00000197323; -.
DR   Orphanet; 146; Papillary or follicular thyroid carcinoma.
DR   PharmGKB; PA38118; -.
DR   eggNOG; ENOG410ITFN; Eukaryota.
DR   eggNOG; ENOG410Z421; LUCA.
DR   GeneTree; ENSGT00870000136392; -.
DR   HOVERGEN; HBG054599; -.
DR   InParanoid; Q9UPN9; -.
DR   KO; K08883; -.
DR   OMA; NEMSRII; -.
DR   OrthoDB; EOG091G01KK; -.
DR   PhylomeDB; Q9UPN9; -.
DR   TreeFam; TF106455; -.
DR   Reactome; R-HSA-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity.
DR   SignaLink; Q9UPN9; -.
DR   SIGNOR; Q9UPN9; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; TRIM33; human.
DR   GeneWiki; TRIM33; -.
DR   GenomeRNAi; 51592; -.
DR   PMAP-CutDB; Q9UPN9; -.
DR   PRO; PR:Q9UPN9; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000197323; -.
DR   CleanEx; HS_TRIM33; -.
DR   ExpressionAtlas; Q9UPN9; baseline and differential.
DR   Genevisible; Q9UPN9; HS.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0070410; F:co-SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0070412; F:R-SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; TAS:Reactome.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd00162; RING; 1.
DR   Gene3D; 1.20.920.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 3.
DR   InterPro; IPR003649; Bbox_C.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR019786; Zinc_finger_PHD-type_CS.
DR   InterPro; IPR027370; Znf-RING_LisH.
DR   InterPro; IPR000315; Znf_B-box.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   Pfam; PF00439; Bromodomain; 1.
DR   Pfam; PF00628; PHD; 1.
DR   Pfam; PF00643; zf-B_box; 1.
DR   Pfam; PF13445; zf-RING_UBOX; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00502; BBC; 1.
DR   SMART; SM00336; BBOX; 2.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM00249; PHD; 2.
DR   SMART; SM00184; RING; 2.
DR   SUPFAM; SSF47370; SSF47370; 1.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   PROSITE; PS50014; BROMODOMAIN_2; 1.
DR   PROSITE; PS50119; ZF_BBOX; 2.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Bromodomain;
KW   Chromosomal rearrangement; Coiled coil; Complete proteome;
KW   DNA-binding; Isopeptide bond; Metal-binding; Methylation; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat; Repressor;
KW   Transcription; Transcription regulation; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1   1127       E3 ubiquitin-protein ligase TRIM33.
FT                                /FTId=PRO_0000056395.
FT   DOMAIN      974   1046       Bromo. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00035}.
FT   ZN_FING     125    154       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   ZN_FING     212    259       B box-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00024}.
FT   ZN_FING     271    312       B box-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00024}.
FT   ZN_FING     887    934       PHD-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   REGION        1    147       Necessary for E3 ubiquitin-protein ligase
FT                                activity and repression of SMAD4
FT                                signaling and transcriptional repression.
FT   REGION      299    401       Necessary for oligomerization.
FT   COILED      299    401       {ECO:0000255}.
FT   COMPBIAS     13     18       Poly-Gly.
FT   COMPBIAS     44     49       Poly-Glu.
FT   COMPBIAS    545    550       Poly-Thr.
FT   SITE        964    965       Breakpoint for translocation to form
FT                                TRIM33-RET oncogene.
FT   MOD_RES     515    515       Asymmetric dimethylarginine; alternate.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     515    515       Omega-N-methylarginine; alternate.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     535    535       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     577    577       Asymmetric dimethylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     591    591       Asymmetric dimethylarginine; alternate.
FT                                {ECO:0000250|UniProtKB:Q99PP7}.
FT   MOD_RES     591    591       Omega-N-methylarginine; alternate.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     598    598       Asymmetric dimethylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     604    604       Asymmetric dimethylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     763    763       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     769    769       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     793    793       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:Q99PP7}.
FT   MOD_RES     803    803       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q99PP7}.
FT   MOD_RES     815    815       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q99PP7}.
FT   MOD_RES     862    862       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     951    951       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q99PP7}.
FT   MOD_RES     953    953       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1051   1051       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1102   1102       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1105   1105       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1119   1119       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK    334    334       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447}.
FT   CROSSLNK    763    763       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate. {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:25772364}.
FT   CROSSLNK    769    769       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate. {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:25772364}.
FT   CROSSLNK    776    776       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000244|PubMed:25114211}.
FT   CROSSLNK    776    776       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25114211,
FT                                ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:25772364}.
FT   CROSSLNK    793    793       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1);
FT                                alternate. {ECO:0000244|PubMed:25114211}.
FT   CROSSLNK    793    793       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate. {ECO:0000244|PubMed:25114211,
FT                                ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:25772364}.
FT   CROSSLNK    861    861       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25772364}.
FT   CROSSLNK    953    953       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate. {ECO:0000244|PubMed:25218447}.
FT   CROSSLNK   1007   1007       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447}.
FT   CROSSLNK   1057   1057       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:25772364}.
FT   CROSSLNK   1118   1118       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25772364}.
FT   VAR_SEQ    1041   1057       Missing (in isoform Beta).
FT                                {ECO:0000303|PubMed:10439047,
FT                                ECO:0000303|PubMed:11331580}.
FT                                /FTId=VSP_005774.
FT   VARIANT      67     67       V -> A (in dbSNP:rs6691166).
FT                                /FTId=VAR_029494.
FT   VARIANT     580    580       M -> I (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042376.
FT   VARIANT     696    696       L -> S (in dbSNP:rs56151583).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042377.
FT   VARIANT     811    811       E -> K (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042378.
FT   VARIANT     840    840       I -> T (in dbSNP:rs6537825).
FT                                {ECO:0000269|PubMed:10022127,
FT                                ECO:0000269|PubMed:10439047,
FT                                ECO:0000269|PubMed:10470851,
FT                                ECO:0000269|PubMed:11331580}.
FT                                /FTId=VAR_024616.
FT   VARIANT     885    885       P -> S (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042379.
FT   VARIANT     961    961       V -> M (in dbSNP:rs55688622).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042380.
FT   VARIANT    1090   1090       P -> T (in dbSNP:rs55784699).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042381.
FT   MUTAGEN     125    125       C->A: Abolishes E3 activity but does not
FT                                affect interaction with SMAD4; when
FT                                associated with A-128.
FT                                {ECO:0000269|PubMed:15820681}.
FT   MUTAGEN     128    128       C->A: Abolishes E3 activity but does not
FT                                affect interaction with SMAD4; when
FT                                associated with A-125.
FT                                {ECO:0000269|PubMed:15820681}.
FT   CONFLICT     89     89       V -> E (in Ref. 5; CAB55313).
FT                                {ECO:0000305}.
FT   CONFLICT    451    453       PAA -> LLH (in Ref. 5; CAB55313).
FT                                {ECO:0000305}.
FT   CONFLICT    909    909       F -> S (in Ref. 5; CAB55313).
FT                                {ECO:0000305}.
FT   CONFLICT   1037   1037       R -> T (in Ref. 1; AAD17259).
FT                                {ECO:0000305}.
FT   STRAND      888    890       {ECO:0000244|PDB:3U5N}.
FT   TURN        891    893       {ECO:0000244|PDB:3U5N}.
FT   STRAND      897    901       {ECO:0000244|PDB:3U5N}.
FT   STRAND      903    906       {ECO:0000244|PDB:3U5N}.
FT   TURN        911    913       {ECO:0000244|PDB:3U5N}.
FT   STRAND      914    916       {ECO:0000244|PDB:3U5N}.
FT   STRAND      918    920       {ECO:0000244|PDB:3U5P}.
FT   TURN        929    931       {ECO:0000244|PDB:3U5N}.
FT   STRAND      934    936       {ECO:0000244|PDB:3U5N}.
FT   HELIX       944    947       {ECO:0000244|PDB:3U5O}.
FT   HELIX       960    974       {ECO:0000244|PDB:3U5N}.
FT   HELIX       980    982       {ECO:0000244|PDB:3U5N}.
FT   HELIX       993    996       {ECO:0000244|PDB:3U5N}.
FT   HELIX      1003   1010       {ECO:0000244|PDB:3U5N}.
FT   STRAND     1011   1013       {ECO:0000244|PDB:3U5O}.
FT   HELIX      1021   1045       {ECO:0000244|PDB:3U5N}.
FT   HELIX      1061   1080       {ECO:0000244|PDB:3U5N}.
FT   STRAND     1081   1083       {ECO:0000244|PDB:3U5O}.
SQ   SEQUENCE   1127 AA;  122533 MW;  7A36013799E9933C CRC64;
     MAENKGGGEA ESGGGGSGSA PVTAGAAGPA AQEAEPPLTA VLVEEEEEEG GRAGAEGGAA
     GPDDGGVAAA SSGSAQAASS PAASVGTGVA GGAVSTPAPA PASAPAPGPS AGPPPGPPAS
     LLDTCAVCQQ SLQSRREAEP KLLPCLHSFC LRCLPEPERQ LSVPIPGGSN GDIQQVGVIR
     CPVCRQECRQ IDLVDNYFVK DTSEAPSSSD EKSEQVCTSC EDNASAVGFC VECGEWLCKT
     CIEAHQRVKF TKDHLIRKKE DVSESVGASG QRPVFCPVHK QEQLKLFCET CDRLTCRDCQ
     LLEHKEHRYQ FLEEAFQNQK GAIENLLAKL LEKKNYVHFA ATQVQNRIKE VNETNKRVEQ
     EIKVAIFTLI NEINKKGKSL LQQLENVTKE RQMKLLQQQN DITGLSRQVK HVMNFTNWAI
     ASGSSTALLY SKRLITFQLR HILKARCDPV PAANGAIRFH CDPTFWAKNV VNLGNLVIES
     KPAPGYTPNV VVGQVPPGTN HISKTPGQIN LAQLRLQHMQ QQVYAQKHQQ LQQMRMQQPP
     APVPTTTTTT QQHPRQAAPQ MLQQQPPRLI SVQTMQRGNM NCGAFQAHQM RLAQNAARIP
     GIPRHSGPQY SMMQPHLQRQ HSNPGHAGPF PVVSVHNTTI NPTSPTTATM ANANRGPTSP
     SVTAIELIPS VTNPENLPSL PDIPPIQLED AGSSSLDNLL SRYISGSHLP PQPTSTMNPS
     PGPSALSPGS SGLSNSHTPV RPPSTSSTGS RGSCGSSGRT AEKTSLSFKS DQVKVKQEPG
     TEDEICSFSG GVKQEKTEDG RRSACMLSSP ESSLTPPLST NLHLESELDA LASLENHVKI
     EPADMNESCK QSGLSSLVNG KSPIRSLMHR SARIGGDGNN KDDDPNEDWC AVCQNGGDLL
     CCEKCPKVFH LTCHVPTLLS FPSGDWICTF CRDIGKPEVE YDCDNLQHSK KGKTAQGLSP
     VDQRKCERLL LYLYCHELSI EFQEPVPASI PNYYKIIKKP MDLSTVKKKL QKKHSQHYQI
     PDDFVADVRL IFKNCERFNE MMKVVQVYAD TQEINLKADS EVAQAGKAVA LYFEDKLTEI
     YSDRTFAPLP EFEQEEDDGE VTEDSDEDFI QPRRKRLKSD ERPVHIK
//
